Skip to main content

Table 1 Baseline characteristics of the present cohort at the time of the index exacerbation

From: Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial

 

Present cohort n = 178

Age, years, mean (range)

69 (42-91)

Female gender, n (%)

62 (35)

Oxygen saturation in %, mean (SD)

88 (7)

Systolic blood pressure in mmHg, mean (SD)

142 (26)

Heart rate, per minute, mean (SD)

93 (19)

Temperature (°C), mean (SD)

37.5 (84)

14 days glucocorticoid treatment n (%)

96 (54)

5 days glucocorticoid treatment n (%)

82 (46)

COPD GOLD grade, n (%)

 

 I

24 (13)

 II

60 (34)

 III

94 (53)

 IV

0

Dyspnea Score (Scale 1-5), n (%)

 

 1

5 (3)

 2

17 (10)

 3

22 (12)

 4

50 (28)

 5

76 (43)

 NA

8 (4)

Home oxygen requirement, n (%)

 

 Yes

21 (12)

 No

156 (87)

 NA

1 (1)

Smoking status, n (%)

 

 Active

80 (45)

 Stopped

98 (55)

 NA

0 (0)

Glucocorticoid treatment before admission (iv + oral), n (%)

 

 Yes

34 (19)

 No

144 (81)

 NA

0 (0)

Antibiotic treatment before admission, n (%)

 

 Yes

33 (19)

 No

144 (80)

 NA

1 (1)

Outcome

 

Re-exacerbation within 180 days, n (%)

 

 Overall

65 (36)

 5 days glucocorticoid group

24 (29), n=82

 14 days glucocorticoid group

41 (43), n=96

Death within 180 days, n (%)

 

 Overall

7 (4)

 5 days glucocorticoid group

3 (4), n=82

 14 days glucocorticoid group

4 (4), n=96

Death or exacerbation within 180 days, n (%)

 

 Overall

67 (38)

 5 days glucocorticoid group

24 (29), n=82

 14 days glucocorticoid group

43 (45), n=96

  1. Clinical characteristics were assessed when patients were admitted to the hospital
  2. SD standard deviation, COPD Chronic obstructive pulmonary disease, d day, NA not available